Sage Therapeutics Inc (SAGE)
13.58
-0.42
(-3.00%)
USD |
NASDAQ |
Apr 25, 16:00
13.60
+0.02
(+0.11%)
After-Hours: 20:00
Sage Therapeutics Net Income (Quarterly): -32.71M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -32.71M |
| September 30, 2023 | -201.63M |
| June 30, 2023 | -160.32M |
| March 31, 2023 | -146.83M |
| December 31, 2022 | -147.15M |
| September 30, 2022 | -137.32M |
| June 30, 2022 | -126.26M |
| March 31, 2022 | -122.06M |
| December 31, 2021 | -124.71M |
| September 30, 2021 | -130.17M |
| June 30, 2021 | -107.24M |
| March 31, 2021 | -95.76M |
| December 31, 2020 | 974.90M |
| September 30, 2020 | -105.74M |
| June 30, 2020 | -136.35M |
| March 31, 2020 | -126.74M |
| December 31, 2019 | -168.65M |
| September 30, 2019 | -179.96M |
| June 30, 2019 | -168.22M |
| March 31, 2019 | -163.41M |
| December 31, 2018 | -158.39M |
| September 30, 2018 | -122.92M |
| Date | Value |
|---|---|
| June 30, 2018 | -16.98M |
| March 31, 2018 | -74.60M |
| December 31, 2017 | -69.42M |
| September 30, 2017 | -73.72M |
| June 30, 2017 | -70.20M |
| March 31, 2017 | -56.78M |
| December 31, 2016 | -55.90M |
| September 30, 2016 | -37.80M |
| June 30, 2016 | -34.75M |
| March 31, 2016 | -30.54M |
| December 31, 2015 | -28.56M |
| September 30, 2015 | -24.04M |
| June 30, 2015 | -25.03M |
| March 31, 2015 | -16.87M |
| December 31, 2014 | -12.36M |
| September 30, 2014 | -9.468M |
| June 30, 2014 | -6.192M |
| March 31, 2014 | -5.79M |
| December 31, 2013 | -5.718M |
| September 30, 2013 | -4.519M |
| June 30, 2013 | -4.655M |
| March 31, 2013 | -3.389M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-201.63M
Minimum
Sep 2023
974.90M
Maximum
Dec 2020
-75.94M
Average
-130.17M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
| Biogen Inc | 393.40M |
| Perspective Therapeutics Inc | -24.68M |
| Vanda Pharmaceuticals Inc | -2.40M |
| ADMA Biologics Inc | -17.64M |
| Finch Therapeutics Group Inc | -3.041M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 77.97M |
| Total Expenses (Quarterly) | 120.26M |
| EPS Diluted (Quarterly) | -0.54 |
| Enterprise Value | 63.06M |
| Gross Profit Margin (Quarterly) | 98.95% |
| Profit Margin (Quarterly) | -41.95% |
| Earnings Yield | -66.64% |
| Normalized Earnings Yield | -62.54 |